Sienna Biopharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | |
|---|---|---|---|
| Revenue | $0 | — | — |
| Operating income | −$76.5M | −$48.6M | −$20.7M |
| Net income | −$17.1M | −$10.1M | −$21.2M |
| Total assets | $107.3M | $136.8M | $62.4M |
| Total liabilities | $80.7M | $45.6M | $40.3M |
| Equity | $26.6M | $91.2M | $22.1M |
| EPS (diluted) | — | — | — |
| Shares out. | 20.7M | 20.2M | 1.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −64.3%
- Return on assets
- −15.9%
- Return on capital (ROCE)
- −92.2%
- Liabilities / assets
- 75.2%
- Debt / equity
- 3.04×
- Book value / share
- $1.28
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -7.69distress
- Accruals / assets
- 41.6%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 0 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Azoy AlexanderOfficer — Chief Financial Officer | Oct 2, 2019 | Tax withholding | 2,396 | $0.23 |
| Andrews Timothy K.Officer — General Counsel & Secretary | Aug 6, 2019 | Grant | 50,000 | — |
| Azoy AlexanderOfficer — Chief Financial Officer | Aug 6, 2019 | Grant | 70,000 | — |
| Lizzul Paul F.Officer — Chief Medical Officer | Aug 6, 2019 | Grant | 55,000 | — |
| Beddingfield Iii FrederickOfficer — President & CEO | Aug 6, 2019 | Grant | 150,000 | — |
| Stroehmann DianeOfficer — See Remarks | Jul 2, 2019 | Tax withholding | 4,095 | $0.76 |
| Andrews Timothy K.Officer — General Counsel & Secretary | Jul 2, 2019 | Tax withholding | 4,095 | $0.76 |
| Lizzul Paul F.Officer — Chief Medical Officer | Jul 2, 2019 | Tax withholding | 4,095 | $0.76 |
| Azoy AlexanderOfficer — Chief Financial Officer | Jul 2, 2019 | Tax withholding | 1,552 | $0.76 |
| Beddingfield Iii FrederickOfficer — President & CEO | Jul 2, 2019 | Tax withholding | 17,063 | $0.76 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Other material eventDec 11, 2019
- Other material eventNov 15, 2019
- Other material eventOct 17, 2019
- Delisting / listing-standard notice · Other material eventSep 23, 2019
- Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer changeSep 17, 2019
- Delisting / listing-standard noticeAug 14, 2019
- Shareholder voteJun 3, 2019
- Results of operationsMay 8, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.